BioCryst Pharmaceuticals | DEBITO





DEBITO Cambiamento Data
Alnylam Pharmaceuticals USD 1.3B 271.5M 2025-06
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Chugai Pharma JPY 14.11B 1.93B 2022-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 24.94B 5M 2025-09
GlaxoSmithKline GBP 17.75B 396M 2025-09
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 41.27M 1.14M 2025-09
Ionis Pharmaceuticals USD 1.23B 192.99M 2025-09
Karyopharm Therapeutics USD 264.09M 39.31M 2024-09
Neurocrine Biosciences USD 439.1M 8.4M 2025-06
Novavax USD 233.31M 4.23M 2024-09
PTC Therapeutics USD 286.32M 306K 2025-09
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.35B 215.59M 2025-06
Ultragenyx Pharmaceutical USD 36.3M 1.98M 2025-06
Vertex Pharmaceuticals USD 1.53B 121.7M 2025-06


BioCryst Pharmaceuticals DEBITO - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.